Last updated on December 2016

Phase 3 Study of KHK7580

Brief description of study

This long-term study is designed to evaluate safety and efficacy of KHK7580 orally administered once daily for 52 weeks for patients with secondary hyperparathyroidism receiving hemodialysis.

Clinical Study Identifier: NCT02549404


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kyowa Hakko Kirin

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin
Tokyo, Japan
  Connect »